Tongyuan Kang Pharma's $56M Equity Subscription with Qilu Pharma Collapses Amid Legal Disputes
TYK Medicines (Tongyuan Kang) announced on September 20 that its HK$400 million H-share subscription agreement with Qilu Pharmaceutical has lapsed after conditions were unmet. The equity deal was part of a broader collaboration valued up to CNY 2.7 billion for TY-9591, a third-generation EGFR inhibitor. While the licensing agreement remains in place, TY-9591 is entangled in a legal ownership dispute with Huiyu Pharmaceutical, which claims exclusive national distribution rights. Two lawsuits have been filed but not yet tried.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Common ground
- Both sides agree that the hybrid equity-license model is a necessary adaptation in China's fast-growing pharma sector, but it carries risks.
- There is agreement that external factors like US rate hikes and geopolitical tensions hurt Chinese biotech stocks, though they disagree on how much blame those factors deserve.
- Both acknowledge that the Huiyu distribution rights dispute shows China's courts are involved in resolving commercial conflicts, which is a sign of legal function.
Points of contention
- Eastern Agent says the 67% premium Qilu paid was based on the drug's real value, while Neutral Agent says it was a bad bet ignoring market signals.
- Eastern Agent sees the Huiyu dispute as normal growing pains and progress, while Neutral Agent calls it sloppy contract management that should have been caught.
- Neutral Agent argues the hybrid model is structurally flawed because the license fails when the equity deal collapses, but Eastern Agent says it works under stable conditions and blames external pressures.
Blind spots
- Both sides overlook how the deal's failure might affect patients who need TY-9591, focusing only on business and legal angles.
- Neither discusses the role of smaller investors in TYK Medicines who lost money when the stock crashed.
- The debate misses the possibility that clearer government guidelines could prevent such contract disputes in the future.
WorldAttention’s read
The roundtable shows a clear split: Eastern Agent views the Tongyuan Kang case as a normal stress test in China's fast-moving pharma sector, where growing pains and legal disputes are signs of progress, not failure. Neutral Agent sees it as a preventable mess caused by poor due diligence, overpaying for a risky asset, and a flawed deal structure that left the license vulnerable. Both agree the hybrid equity-license model is a necessary tool in China's market, but they clash on whether its risks are manageable or fatal. The main blind spots are the human impact on patients and investors, and the potential for government rules to reduce such conflicts. In the end, the debate highlights that Chinese pharma is learning fast, but it still needs to tighten its legal and financial practices to avoid repeating the same mistakes.
Reporting timeline
Qilu Pharma's $370M Deal with TYK Medicines Fails; Core Pipeline Faces Ownership Dispute
TYK Medicines (Tongyuan Kang) announced the formal lapse of a HKD 400 million H-share subscription agreement with Qilu Pharmaceutical, ending a key component of a deal valued up to CNY 2.7 billion. The composite transaction, combining a pipeline license for TY-9591 with an equity investment, saw the capital tie severed after conditions were unmet. While the license agreement remains technically in place, the core asset TY-9591 is entangled in a legal ownership dispute with Huiyu Pharmaceutical, with two lawsuits filed but not yet tried. The article attributes the failure to multiple factors, including market conditions and unresolved legal risks. It further notes that this is not Qilu's first setback in innovative BD, citing prior cases with Rigel Therapeutics (a governance dispute) and Lisata Therapeutics (a terminated license after acquisition). The analysis argues that the episode exposes deep weaknesses in traditional pharma companies' transition to innovative BD, including complex deal structures, inadequate due diligence on historical contracts, and poor risk management of biotech governance and overseas capital changes. The author forecasts that the outcome of the litigation and Qilu's subsequent strategy will be key to the deal's ultimate fate.
Read sourceTongyuan Kang's $56M equity subscription with Qilu Pharma fails amid legal disputes
Tongyuan Kang Pharmaceutical (同源康医药) announced on September 20 that its equity subscription agreement with Qilu Pharmaceutical (齐鲁制药) has lapsed, as conditions for the deal were not met. The agreement, part of a broader collaboration on the core drug TY-9591, would have seen Qilu subscribe to 63.22 million new H-shares at HK$7.30 each, totaling about 400 million yuan ($56 million). The failure is attributed to market conditions and recent share price declines; Tongyuan Kang's stock closed at HK$3.255 on September 20, down from the agreed subscription price. This follows a separate legal dispute with Huiyu Pharmaceutical (汇宇制药) over the national distribution rights for TY-9591, which was filed shortly after the Qilu deal was signed. TY-9591, a third-generation EGFR inhibitor for non-small cell lung cancer, received conditional market approval in late August but faces intense competition from AstraZeneca, Hansoh Pharma, and Allist Pharma. Tongyuan Kang has no prior commercial revenue and reported losses of 300 million yuan in 2025 and 26.88 million yuan in the first half of 2026. Experts quoted in the article warn that the legal dispute and market competition pose significant risks to the company's commercialization prospects and financial stability.
Read sourceTongyuan Kang loses Qilu Pharma's equity subscription after licensing dispute
Tongyuan Kang Pharmaceutical announced on September 20 that its share subscription agreement with Qilu Pharmaceutical had lapsed, as certain conditions were not met by the final deadline. The deal, valued at approximately 4 billion Hong Kong dollars, was part of a larger licensing agreement for Tongyuan Kang's core drug TY-9591, a derivative of the cancer drug Osimertinib. The subscription would have made Qilu a major shareholder with a 14.26% stake. The failure follows a legal dispute with Huiyu Pharmaceutical, which claims it holds exclusive national distribution rights to TY-9591 from a 2026 agreement. Tongyuan Kang stated the lapse will not materially affect its operations and that both parties remain willing to negotiate. The company's stock rose 15% on September 21 despite the setback. The article notes that the subscription price of 7.30 HKD per share was above the market price at the time of expiry, which may have contributed to the decision not to extend the deadline. Tongyuan Kang has no revenue and reported a loss of 26.9 million yuan in its 2026 interim report.
Read sourceShow 2 older updatesHide older updates
TYK Medicines' $56M equity subscription with Qilu Pharma fails amid legal disputes and stock plunge
TYK Medicines (Tongyuankang Pharmaceutical) announced on September 20 that its equity subscription agreement with Qilu Pharmaceutical, valued at approximately 400 million yuan ($56 million), has lapsed due to unmet conditions and recent stock price declines. The subscription, at 7.3 HKD per share, was part of a broader collaboration for the commercialization of TYK's core drug TY-9591, a third-generation EGFR inhibitor for non-small cell lung cancer. The stock had fallen to 3.255 HKD by the deadline. Separately, TYK is embroiled in a legal dispute with Huiyu Pharmaceutical over the exclusive distribution rights for TY-9591, filed the day after the Qilu deal was signed. TY-9591 received conditional market approval in late August but faces intense competition from AstraZeneca, Hansoh Pharma, and Allist Pharma. TYK has no prior commercial revenue and reported losses of 300 million yuan in 2025 and 26.88 million yuan in the first half of 2026. Analysts cited in the article warn that the legal uncertainty, competitive market, and lack of revenue pose significant challenges to TYK's commercialization prospects and financial stability.
Read sourceTongyuan Kang Pharma's $56M Equity Subscription with Qilu Pharma Collapses Amid Legal Disputes
Tongyuan Kang Pharmaceutical (同源康医药) announced on September 20 that its equity subscription agreement with Qilu Pharmaceutical (齐鲁制药) has formally lapsed after conditions were not met. The deal, part of a broader collaboration on core drug TY-9591 (a third-generation EGFR inhibitor for non-small cell lung cancer), involved Qilu subscribing to 63.22 million new H-shares at HK$7.30 each, totaling about HK$400 million (US$51 million). The subscription price was more than double Tongyuan Kang's closing price of HK$3.255 on September 20. The company stated the lapse will not materially affect operations and both parties will continue their licensing and commercialization agreements. Separately, Tongyuan Kang faces a legal dispute with Huiyu Pharmaceutical (汇宇制药) over TY-9591's distribution rights, filed days after the Qilu deal. Huiyu claims a prior exclusive national distribution agreement signed in February 2025, while Tongyuan Kang seeks to void it. Analysts cited by Beijing Business Today warn the legal uncertainty could complicate future licensing deals and investor confidence. TY-9591 received conditional NMPA approval in August 2025 but faces intense competition from AstraZeneca, Hansoh Pharma, and Allist Pharma. Tongyuan Kang has no prior commercial revenue and reported losses of 300 million yuan in 2025 and 26.88 million yuan in H1 2026.